This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.

For years, the dominant fear about stopping semaglutide or tirzepatide has been simple: stop the drug, regain more than half the weight within a year. That fear came almost entirely from randomized clinical trials, where patients who stopped treatment had no ability to switch medications, restart later, or adjust their plan — they simply stopped and were tracked. A new real-world study of nearly 8,000 patients, released by Cleveland Clinic researchers and covered widely this month, tells a meaningfully different story (ScienceDaily, July 12, 2026).

Medical creator Christy Risinger, MD covered this exact study on her channel on July 9, 2026, calling it one of the more reassuring pieces of GLP-1 research to emerge this year — a signal of just how much attention this data is getting right now. Here's what the study actually found, why the numbers differ so much from earlier trial data, and what it means if you're currently thinking about stopping.

The Study: What Researchers Actually Did

Researchers from Cleveland Clinic's Center for Value-Based Care Research analyzed a retrospective cohort of 7,938 adults with overweight or obesity in Ohio and Florida who had been on injectable semaglutide or tirzepatide for either obesity or type 2 diabetes, then discontinued the medication within a 3-to-12-month window. They tracked what treatment paths patients pursued afterward and how their weight changed over the following year (ScienceDaily).

This is a fundamentally different research design than a randomized controlled trial. In an RCT, once you're assigned to stop the drug, you generally stay in that arm for the study's duration — you don't get to switch treatments or restart based on how you're doing. Real-world clinical practice doesn't work that way, and this study was specifically designed to capture that difference.

Lead Researcher's Explanation

"Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials," said Dr. Hamlet Gasoyan, the study's lead researcher (ScienceDaily).

The Numbers: Obesity Cohort

Patients treated for obesity lost an average of 8.4% of body weight before stopping their medication. In the year after stopping:

  • 55% gained weight
  • 45% either continued losing weight or maintained their existing weight

On average, this group regained just 0.5% of body weight over the following year — a far cry from the "more than half the lost weight" regain figure associated with earlier randomized trial data (ScienceDaily).

The Numbers: Type 2 Diabetes Cohort

Patients treated for type 2 diabetes lost an average of 4.4% of body weight before discontinuation. This group did even better after stopping:

  • 44% gained weight
  • 56% maintained or continued to lose weight

On average, this cohort lost an additional 1.3% of body weight in the year after stopping — meaning, on average, this group kept losing weight even after coming off the medication (ScienceDaily).

Why the Real-World Numbers Look So Different From Trial Data

What Patients Actually Did After Stopping

The study tracked exactly what happened to patients in the year after discontinuation:

  • 27% switched to another medication, including older-generation obesity drugs or switching between semaglutide and tirzepatide
  • 20% restarted their original medication
  • 14% continued treatment through lifestyle-focused care with dietitians or exercise specialists
  • Less than 1% underwent metabolic and bariatric surgery

In other words, the majority of patients in this real-world cohort didn't just stop and walk away — most pursued some kind of follow-up treatment plan, whether that meant restarting, switching, or leaning into structured lifestyle support (ScienceDaily).

The Randomized Trial Comparison

Earlier randomized clinical trials found that patients who stopped semaglutide or tirzepatide regained more than half of the weight they had lost within a year — because trial protocols, by design, don't allow the same flexibility to switch or restart treatment that real-world clinical practice does (ScienceDaily).

How This Fits With Other 2026 Research

This isn't the only maintenance-related study making news in 2026. The SURMOUNT-MAINTAIN trial (Lancet, June 2026) looked at a related but distinct question — what happens to weight when patients reduce their dose rather than stop entirely — and found that continuing at a lower maintenance dose preserved substantially more weight loss than full discontinuation. We break that trial down separately in our GLP-1 maintenance dose guide.

Together, these two 2026 studies paint a more complete picture: full discontinuation without any follow-up plan tends to lead to more weight regain, but there are meaningfully better paths — whether that's a reduced maintenance dose, a treatment switch, or structured lifestyle support — than the "all or nothing" framing that dominated earlier coverage of this topic.

What This Means If You're Thinking About Stopping

The Reassuring Part

If your circumstances require stopping — cost, insurance changes, side effects, or personal choice — this data suggests the outcome is not automatically "regain everything." Real-world patients who stayed engaged with some form of follow-up care did meaningfully better than the doom-and-gloom trial extrapolations suggested.

The Important Caveat

This study's more encouraging numbers are tied directly to the fact that most patients didn't stop and do nothing — they restarted, switched, or added structured support. If you're planning to stop, the data implies that having a follow-up plan in place (with your prescriber, not on your own) is likely a meaningful part of why outcomes were better in this cohort.

What Dr. Gasoyan's Team Plans to Study Next

"Many patients do not give up on their obesity treatment journey, even if they need to stop their initial medication," Dr. Gasoyan said. "In our future work, we will examine the comparative effectiveness of alternative treatment options for obesity in patients who discontinue semaglutide or tirzepatide, to help patients and their clinicians make informed decisions" (ScienceDaily).

If You're Actively Planning to Taper Off

This article focuses on the new research findings. If you're looking for a practical, step-by-step approach to tapering off a GLP-1 medication safely, see our companion guide on stopping GLP-1s without going cold turkey, which covers tapering schedules and what to expect week by week.

Where Patients Went: A Closer Look at the Follow-Up Paths

It's worth sitting with the four follow-up categories the study tracked, because the differences between them are informative for anyone weighing what to do after stopping.

Switching Medications (27%)

This was the single most common path. Some patients switched between semaglutide and tirzepatide — the two dominant modern GLP-1 options — while others moved to older-generation obesity drugs. A switch often happens because of side effects, cost, insurance formulary changes, or simply because a different drug class worked better for that individual's biology.

Restarting the Original Medication (20%)

A fifth of patients who stopped ended up going right back on the same drug within the year. This suggests that for a meaningful share of patients, the initial discontinuation wasn't a permanent decision but more of a pause — whether due to a temporary access gap, a side-effect break, or a cost issue that later resolved.

Structured Lifestyle-Focused Care (14%)

This group continued working with dietitians or exercise specialists after stopping medication, rather than switching to or restarting a drug. It's a reminder that GLP-1 discontinuation doesn't have to mean the end of active weight management support — it can mean a shift in what kind of support.

Metabolic and Bariatric Surgery (Less Than 1%)

Surgery remained a rare next step in this cohort, reinforcing that for the vast majority of patients who stop a GLP-1, medication switching, restarting, or lifestyle support are the far more common paths forward.

Why This Study's Design Matters for Interpreting the Results

Because this is a retrospective cohort study rather than a randomized trial, it can't prove that switching or restarting caused better outcomes in a strict causal sense — patients who proactively sought follow-up care may also differ in other ways (engagement level, access to care, insurance status) from patients who didn't. That's an important limitation to hold alongside the encouraging headline numbers. What the study does establish clearly is the real-world pattern: most patients who stop don't just disappear from treatment entirely, and the group that regains the least weight overlaps heavily with the group that pursued some kind of active follow-up.

Where the Data Came From

The cohort was drawn from patients in Ohio and Florida specifically, which means the findings may not perfectly generalize to other regions with different healthcare access patterns, insurance environments, or demographic makeups. Still, a sample of nearly 8,000 patients is substantial for this kind of real-world analysis, and the consistency between the obesity and diabetes sub-cohorts strengthens confidence in the general pattern.

Educational content only. Not medical advice. Talk to your prescriber before making any changes to a GLP-1 treatment plan.

Frequently Asked Questions

Do you regain all the weight after stopping Ozempic or Mounjaro?

Not necessarily, according to new real-world data. A Cleveland Clinic study of nearly 8,000 patients found 55% of those treated for obesity regained some weight after stopping, but the average regain was just 0.5% of body weight over the following year — far less than earlier trial-based estimates suggested.

Why do real-world results differ so much from clinical trial results?

Because clinical trial protocols typically don't allow patients to switch medications or restart treatment after being assigned to stop. In real-world practice, most patients pursued some follow-up option — restarting (20%), switching medications (27%), or structured lifestyle support (14%) — which appears to meaningfully limit weight regain compared to stopping with no follow-up plan at all.

What journal published this new discontinuation study?

*Diabetes, Obesity and Metabolism*, under the title "Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide" (DOI: 10.1111/dom.70660).

Who led the research?

Dr. Hamlet Gasoyan of Cleveland Clinic's Center for Value-Based Care Research led the study, alongside co-authors including Rebecca Schulte, W. Scott Butsch, Ali Aminian, and Michael B. Rothberg.

Does this study mean it's fine to stop a GLP-1 without medical supervision?

No. The study's more encouraging numbers are tied to patients who had a follow-up plan — restarting, switching, or structured support — not to stopping with no plan at all. Always work with your prescriber before stopping any GLP-1 medication.

Did diabetes patients do better than obesity patients after stopping?

Yes, in this study. 56% of the type 2 diabetes cohort maintained or continued to lose weight after stopping, compared to 45% of the obesity cohort, with the diabetes group gaining an additional 1.3% weight loss on average in the year after discontinuation.

Sources

  1. ScienceDaily — What happens after Ozempic shocked researchers:sciencedaily.com (July 12, 2026)
  2. Gasoyan H, Schulte R, Boyer CB, et al. — Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. *Diabetes, Obesity and Metabolism*, 2026. DOI: 10.1111/dom.70660